Aura Biosciences, Inc.(AURA)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Aura Biosciences, Inc. (AURA) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. AURA is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q2 2026), Aura Biosciences, Inc. reports net income of $-45.6M, free cash flow of $-32.5M. Top institutional holders of AURA by reported 13-F value include TCG Crossover Management, SUVRETTA CAPITAL MANAGEMENT, Frazier Life Sciences Management, L.P., based on the most recent SEC filings. AURA trades on the Nasdaq exchange and files with the SEC under CIK 1501796. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AURA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Aura Biosciences, Inc. directly from SEC EDGAR.